SCHEMBL4193609

SCHEMBL4193609

CCOC(=O)Cc1c(O)ccnc1-c1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.49
HSD17B10 Q99714 2/20 0.49
USP2 O75604 1/20 0.49
TSHR P16473 1/20 0.49
TRPM8 Q7Z2W7 1/20 0.48
SMN1; SMN2 Q16637 3/20 0.47
LMNA P02545 2/20 0.46
L3MBTL1 Q9Y468 3/20 0.46
NPSR1 Q6W5P4 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
KDM4E B2RXH2 4/20 0.45
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
GAA P10253 1/20 0.43
ALDH1A1 P00352 3/20 0.43
HPGD P15428 3/20 0.43
HTT P42858 3/20 0.43
MAPT P10636 1/20 0.43
ATM Q13315 1/20 0.43
ADORA3 P0DMS8 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4186865 0.81 KDM4E (0.46) HSD17B10TSHRSMN1; SMN2LMNAKDM4E
SCHEMBL7651566 0.78 SMN1; SMN2 (0.49) MAPK1HSD17B10USP2TSHRTRPM8
SCHEMBL11253180 0.75 GAA (0.49) MAPK1HSD17B10USP2TSHRTRPM8
SCHEMBL4620807 0.74 S1PR5 (0.36) CYP3A4CYP2C9
SCHEMBL509233 0.73 LMNA (0.55) MAPK1HSD17B10USP2TSHRTRPM8
SCHEMBL9737130 0.73 L3MBTL1 (0.48) MAPK1HSD17B10USP2TSHRSMN1; SMN2
SCHEMBL11499255 0.73 GAA (0.46) TRPM8SMN1; SMN2LMNAL3MBTL1TDP1
SCHEMBL9222213 0.71 MEN1 (0.51) MAPK1HSD17B10USP2TSHRTRPM8
SCHEMBL8548096 0.70 ADORA3 (0.58) MAPK1HSD17B10SMN1; SMN2LMNANPSR1
SCHEMBL23218649 0.70 CA12 (0.53) MAPK1HSD17B10USP2TSHRTRPM8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090105221-A1 MUSCARINIC RECEPTOR ANTAGONISTS RANBAXY LABORATORIES LIMITED (IN) 2009-04-23 US disclosed
EP-1797040-A1 MUSCARINIC RECEPTOR ANTAGONISTS Ranbaxy Laboratories Limited (IN) 2007-06-20 EP disclosed
WO-2006035303-A1 MUSCARINIC RECEPTOR ANTAGONISTS RANBAXY LABORATORIES LIMITED (IN) 2006-04-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105221-A1 MUSCARINIC RECEPTOR ANTAGONISTS CHRM3, CHRM5, CHRM2 MAPK1 1981/4885HSD17B10 2738/4885USP2 3128/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.